Padeliporfin di-potassium - Steba Biotech

Drug Profile

Padeliporfin di-potassium - Steba Biotech

Alternative Names: Padeliporfin - Steba Biotech; Palladium bacteriopheophorbide monolysine taurine; Stakel; TOOKAD Soluble; WST 11

Latest Information Update: 13 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Steba Biotech
  • Developer Memorial Sloan-Kettering Cancer Center; Steba Biotech; Weizmann Institute of Science
  • Class Antineoplastics; Porphyrins; Small molecules
  • Mechanism of Action Photosensitisers; Vascular disrupting agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Registered Prostate cancer
  • Phase I/II Renal cancer
  • Phase I Oesophageal cancer; Urogenital cancer
  • Suspended Choroidal neovascularisation
  • No development reported Cholangiocarcinoma; Non-small cell lung cancer

Most Recent Events

  • 01 Aug 2018 Phase-I clinical trials in Urogenital cancer (Recurrent, Second-line therapy or greater, Inoperable/Unresectable) in USA (IV) (NCT03617003)
  • 24 Jun 2018 Biomarkers information updated
  • 20 Jun 2018 Efficacy data from a phase III trial in Prostate cancer released by Steba Biotech
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top